Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Survodutide
BI 456906, Boehringer Ingelheim dual agonist
A GLP-1/glucagon dual receptor agonist co-developed by Innovent Biologics and Eli Lilly. Mazdutide has shown strong weight loss results in Chinese clinical populations, with Phase 3 data showing up to 17.4% weight loss at 48 weeks. It received approval in China in late 2025 for obesity treatment, making it one of the first dual agonists to reach market anywhere in the world.
A dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim for obesity and metabolic liver disease (MASH/NASH). Unlike tirzepatide (GIP/GLP-1), survodutide activates the glucagon receptor alongside GLP-1, which increases energy expenditure and hepatic fat oxidation. Phase 2 trials showed up to 18.7% weight loss at 46 weeks and significant liver fat reduction, making it a leading candidate for MASH treatment.
Dual agonism of GLP-1 and glucagon receptors, similar to survodutide and pemvidutide. GLP-1 activation suppresses appetite and slows gastric emptying. Glucagon activation increases energy expenditure and hepatic fat oxidation. The dual mechanism targets both sides of the energy balance equation.
Dual agonism of glucagon and GLP-1 receptors. GLP-1 activation reduces appetite and slows gastric emptying. Glucagon activation increases hepatic fat oxidation, energy expenditure, and thermogenesis. The combination targets both caloric intake and energy output, with particular benefit for liver fat reduction — a mechanism not shared by pure GLP-1 agonists.
- Weight management (approved in China)
- Type 2 diabetes (investigational)
- Metabolic syndrome
- Weight management (investigational)
- MASH/NASH treatment (investigational)
- Metabolic syndrome
- Liver fat reduction
- GI side effects (nausea, vomiting, diarrhea)
- Not yet approved outside China
- Potential blood sugar effects from glucagon component
- Long-term safety data still accumulating
- GI side effects (nausea, vomiting, diarrhea) — common in GLP-1 class
- Potential blood sugar effects from glucagon activation
- Still in Phase 3 trials — full safety profile not established
- Injection site reactions
Approved in China (late 2025) for obesity. Not yet submitted to FDA. Global Phase 3 trials ongoing. Represents the first approved GLP-1/glucagon dual agonist globally. US regulatory pathway unclear — may require separate US clinical program.
Currently in Phase 3 trials for obesity (SYNCHRONIZE program) and MASH (LIVERAGE program). Phase 2 data showed 18.7% weight loss at 46 weeks and 87% relative reduction in liver fat. Potential FDA submission expected 2027. Represents a differentiated mechanism from tirzepatide and semaglutide.
- Survodutide for MASH: Phase 2 results (LIVERAGE)
2024 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.